Article content
A London life sciences business scored a “milestone” $23-million investment after its new diabetes treatment proved effective in recent human trials.
Sernova Corp., based at Western University’s research park on Collip Circle, is for the first time getting funding from institutional investors for its cell pouch technology that aims to one day ensure diabetics no longer need insulin injections.
We apologize, but this video has failed to load.
Try refreshing your browser, or London biotech firm wins $23M investment for new diabetes treatment Back to video
“This is incredible for a company in London, Ontario, focused on treatment of Type 1 diabetes,” chief executive Philip Toleikis said.